NEW BRIEF HIGHLIGHTS THE ECONOMIC COSTS OF PHARMACY BENEFIT MANAGERS
Exploring a tool that millions of Americans use every day when paying for prescription drugs, the Pacific Research Institute today released a new research brief exploring how Pharmacy Benefit Managers (PBMs) impact prescription drug costs, access, and patient care.
“Pharmacy Benefit Managers impact more than 260 million Americans when they purchase their prescription drugs, but most people have no idea what they are, or the big impact they play in their health care,” said Dr. Wayne Winegarden, PRI’s Senior Fellow in Business and Economics and the author of the new issue brief. “Our new brief explores the many ways PBM’s affect prescription drugs, especially the access to, and the costs of, the life-savings medicines they depend upon.”
Winegarden’s new brief, The Economic Costs of Pharmacy Benefit Managers: A Review of the Literature. reviews recent studies on PBMs. Among the key findings:
- PBMs have an undue influence over the medicines that patients can access;
- They provide incentives for higher list prices for medications that come with large rebates and discounts; and
- They trigger higher patient co-pays than necessary given the large discrepancy between list prices and the prices people pay at the counter.
Considering the challenges with PBMs, Winegarden argues that the current system needs more transparency to transform what is currently a bloated and expensive system. The CEO of Express Scripts recently said in an interview with CNBC that Anthem was unlikely to extend its contract with the PBM following its 2019 contract expiration. This follows a $15 billion lawsuit that Anthem filed against Express Scripts in March 2016 alleging that the PBM charged excess prices for drugs.
————————-
Dr. Wayne Winegarden is a Senior Fellow in Business and Economics at Pacific Research Institute. He is also the Principal of Capitol Economic Advisors and a Managing Editor for EconoSTATS.
Click here to see the original article on the PRI website.
Recent Posts
-
Seniors in Long-Term Care Could Lose Access to Essential LTC Pharmacy Services Absent Action from Congress
A new study from the Senior Care Pharmacy Coalition (SCPC), the nation’s leading voice for long-term care (LTC) pharmacies, performed by CLA (CliftonLarsonAllen LLP) and with input from ATI Advisory details the significant financial impact Medicare drug price negotiations will have on LTC pharmacies that provide essential, government required services to more than two million seniors and others in long-term care.
-
Senior Care Pharmacy Coalition Congratulates Kentucky Congressman Guthrie on Becoming Chairman of the Powerful House Energy and Commerce Committee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released the following statement today to congratulate Congressman Brett Guthrie on being selected as Chairman of the House Energy and Commerce Committee. “We congratulate Kentucky Congressman Brett Guthrie for being selected Chairman of the House Energy and Commerce Committee,” […]
-
Senior Care Pharmacy Coalition & “Save Senior Rx Care” Release Statement in Support of Rep. Buddy Carter’s ongoing push for PBM Reform in 2024
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, and the Save Senior Rx Care campaign released a statement commending Congressman Buddy Carter’s push for PBM Reform in 2024: “SCPC is thankful for champions like Congressman Buddy Carter, Senator James Lankford, and the 14 other members who participated in […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.